Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Next Previous
Trial Profile

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Lifileucel (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
  • Indications Adenocarcinoma; Carcinoma; Head and neck cancer; Large cell carcinoma; Liver metastases; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Iovance Biotherapeutics

Most Recent Events

  • 15 May 2026 Status changed from recruiting to discontinued, after reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.
  • 08 May 2025 According to an Iovance Biotherapeutics media release, Cohorts 3D and 3E in IOV-COM-202 trial are investigating this regimen to inform a registrational and confirmatory trial design in frontline advanced NSCLC.
  • 08 May 2025 According to an Iovance Biotherapeutics media release, Cohort 1D in the IOV-COM-202 trial will be investigating lifileucel in combination with nivolumab and relatlimab in frontline advanced melanoma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top